Evotec SE 2019 AR2
The report highlights Evotec's successful operational and strategic performance in 2019, marked by the acquisition of Just Biotherapeutics (renamed Just – Evotec Biologics) to expand into biologics. The company successfully issued a €250 million promissory note on the capital market and fully repaid its Aptuit acquisition loan. Operationally, Evotec entered multiple new partnerships and progressed its co-owned pipeline, including Bayer's clinical Phase II trial in chronic cough. Financially, Group revenues increased by 19% to €446.4 million, and adjusted Group EBITDA grew by 29% to €123.1 million.
Company: Evotec SE
Sector: Manufacturing
Country: Germany
Year: 2019
Type: AR2
Pages: 142
Back to company
Evotec SE
Annual Report
The report highlights Evotec's successful operational and strategic performance in 2019, marked by the acquisition of Just Biotherapeutics (renamed Just – Evotec Biologics) to expand into biologics. The company successfully issued a €250 million promissory note on the capital market and fully repaid its Aptuit acquisition loan. Operationally, Evotec entered multiple new partnerships and progressed its co-owned pipeline, including Bayer's clinical Phase II trial in chronic cough. Financially, Group revenues increased by 19% to €446.4 million, and adjusted Group EBITDA grew by 29% to €123.1 million.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees